Abstract 379P
Background
Nasopharyngeal carcinoma (NPC) is one of the most prevalent head and neck cancers in South East Asia. Most patients with NPC are presented with intermediate-stage or locally advanced disease requiring chemoradiation as the primary treatment of choice. Epidermal Growth Factor Receptor (EGFR) was found overexpressed in NPC patients. This study aimed to assess the real-world clinical efficacy of combination of nimotuzumab, a humanized anti-EGFR monoclonal antibody and concurrent chemoradiation in NPC patients.
Methods
This retrospective chart reviewed examined a sample of locally advanced NPC patients who were treated with or without adding nimotuzumab to concurrent chemoradiation at Dr. Cipto Mangunkusumo General Hospital in Indonesia from January 2009 to December 2017. Real-world overall survival (rwOS) and progression-free survival (rwPFS) were compared using Kaplan-Meier analysis and Cox proportional hazard models adjusting for age, gender, comorbidities, WHO classification, clinical staging, and types of radiotherapy.
Results
76 patients receiving concurrent nimotuzumab and chemoradiation while 353 patients receiving chemoradiation alone were included in the analysis. Patients treated with concurrent nimotuzumab and chemoradiation tended to have less aggressive NPC than patients treated with chemoradiation alone. Multivariate-adjusted Cox models revealed that adding nimotuzumab to chemoradiation was associated with a statistically significant rwOS gain [hazard ratio (HR)=0.56 (95% CI:0.32-0.96, p=0.0328)] and a trend of longer rwPFS [hazard ratio (HR)=0.75 (95% CI:0.46-1.21, p=0.243)] in comparison to chemoradiation alone.
Conclusions
In this retrospective real-world study of intermediate stage and locally advanced NPC patients, concurrent nimotuzumab and chemoradiation was associated with a significant overall survival benefit than chemoradiation alone. Hence, the combination of nimotuzumab and chemoradiation should be considered in intermediate stage and locally advanced NPC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr Cipto Mangunkusumo General Hospital, Jakarta.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract